PHASE III RANDOMIZED OPEN-LABEL MULTICENTER STUDY EVALUATING EFFICACY AND SAFETY OF MOSUNETUZUMAB IN COMBINATION WITH LENALIDOMIDE IN COMPARISON TO RITUXIMAB IN COMBINATION WITH LENALIDOMIDE WITH A NON RANDOMIZED SINGLE ARM US EXTENSION OF MOSUNETUZUMA

Are you eligible to participate in this study?

You may be eligible for this study if you meet the following criteria:

  • Conditions:
    Follicular Lymphoma
  • Age: Between 18 Year(s) - 100 Year(s)
  • Gender: Male or Female
  • Other Inclusion Criteria:
    1) Eastern Cooperative Oncology Group (ECOG) Performance Status of 0, 1, or 2. 2) Histologically documented CD20+FL(Grade 1-3a). 3) Received at least one prior systemic lymphoma therapy, which included prior immunotherapy or chemoimmunotherapy.

You may not be eligible for this study if the following are true:

  • 1) History of transformation of indolent disease to diffuse-large B cell lymphoma. 2) Documented refractoriness to lenalidomide, defined as no response (partial response or complete response) or relapse within 6 months of therapy. 3) Active or his


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.